Remnant lipoprotein cholesterol and trigly ceride reference ranges from the Framingham heart study

Clinical Chemistry

Volumn 44, Issue 6, 1998, Pages 1224-1232

  Mcnamara, Judith R ^a,b   Shah, Paulesh K ^a,b   Nakajima, Katsuyuki ^c   Cupples, L Adrienne ^d   Wilson, Peter W F ^e   Ordovas, Jose M ^a,b   Schaefer, Ernst J ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; AGING; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CORONARY RISK; DIAGNOSTIC VALUE; FAMILY HISTORY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; POSTMENOPAUSE; RISK ASSESSMENT; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0031745984     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.6.1224     Document Type: Article

References (49)

1. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoproteins as a protective factor against coronary heart disease. Am J Med 1977;62:707-14.
2. Cambien F, Jacqueson A, Richard JL, Wamet JM, Ducimetiere P, Claude JR. Is the level of serum triglyceride a significant predictor of coronary death in "normotriglyceridemic" subjects? Am J Epidemiol 1986;124:624-32.
3. Criqui MH, Heiss G, Cohn R, Cowan LD, Suchindran CM, Bangdiwala S, et al. Plasma triglyceride level and mortality from coronary heart disease. New Eng J Med 1993;328:1220-5.
4. Havel RJ. Origin, metabolic fate and metabolic function of plasma lipoproteins. In: Steinberg D, Olefsky JM, eds. Contemporary issues in endocrinology and metabolism, Vol. 3. New York: Churchill Livingstone 1986:117-41.
5. Havel RJ. Triglyceride-rich lipoproteins. In: Rifai N, Warnick GR, Dominiczak MH, eds. Handbook of lipoprotein testing, 3rd ed. Washington, DC: AACC Press 1997:451-64.
6. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979;60:473-85.
7. Havel RJ. The role of the liver in atherosclerosis. Arteriosclerosis 1985;5:569-80.
8. Norestgaard BG, Tybjaerg-Hansen A. IDL, VLDL, chylomicrons and atherosclerosis. Eur J Epidemiol 1992;8(Suppl):92-8.
9. Rapp JH, Lespine A, Hamilton RL, Colyvas N, Chaumeton AH, Tweedie-Hardman J, et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb 1994;14:1767-74.
10. Davignon J, Cohn JS. Triglycerides: a risk factor for coronary heart disease. Atherosclerosis 1996;124 (Suppl):S57-64.
11. McNamara JR, Cole TG, Contois JH, Ferguson CA, Ordovas JM, Schaefer EJ. Immunoseparation method for measuring low-density lipoprotein cholesterol directly from serum evaluated. Clin Chem 1995;41:232-40.
12. Jialal I, Hirany SV, Devaraj S, Sherwood TA. Comparison of an immunoseparation method for direct measurement of LDL cholesterol with beta-quantification (ultracentrifugation). Am J Clin Path 1995;104:76-81.
13. Pisani T, Gebski CP, Leary ET, Wamick GR, Ollington JF. Accurate direct determination of low-density lipoprotein cholesterol using an immunoseparation reagent and enzymatic cholesterol assay. Arch Pathol Lab Med 1995;119:1127-35.
14. 2Ca. J Physiol 1957;49:83-6.
15. 2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 1982;28:1379-88.
16. Campos E, Nakajima K, Tanaka A, Havel RJ. Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100. J Lipid Res 1992;33:369-80.
17. Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta 1993;223:53-71.
18. Nakajima K, Okazaki M, Tanaka A, Pullinger CR, Wang T, Nakano T, et al. Separation and determination of remnant-like particles in human serum using monoclonal antibodies to apo B-100 and apo A-I. J Clin Ligand Assay 1996;19:177-83.
19. Weintraub MS, Eisenberg S, Breslow JL. Different patterns of postprandial lipoprotein metabolism in normal, Type IIa, Type III, and Type IV hyperlipoproteinemic individuals: Effects of treatment with cholestyramine and gemfibrozil. J Clin Invest 1987;79: 1110-9.
20. Cohn JS, McNamara JR, Cohn SD, Ordovas JM, Schaefer EJ. Postprandial plasma lipoprotein changes in human subjects of different ages. J Lipid Res 1988;29:469-79.
21. Cohn JS, McNamara JR, Cohn SD, Ordovas JM, Schaefer EJ. Plasma apolipoprotein changes in the triglyceride-rich lipoprotein fraction of human subjects fed a fat-rich meal. J Lipid Res 1988;29:925-36.
22. Cohn JS, McNamara JR, Krasinski SD, Russell RM, Schaefer EJ. Role of triglyceride-rich lipoproteins from the liver and intestine in the etiology of postprandial peaks in plasma triglyceride concentration. Metabolism 1989;38:484-90.
23. Cohn JS, Johnson EJ, Millar JS, Cohn SD, Milne RW, Marcel YL, et al. Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters. J Lipid Res 1993;34:2033-40.
24. Wilson PWF, Christianson JC, Anderson K, Kannel WB. Impact of national guidelines for cholesterol risk factor screening: the Framingham Offspring Study. JAMA 1989;262:41-4.
25. McNamara JR, Schaefer EJ. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta 1987;166:1-8.
26. Contois JH, McNamara JR, Lammi-Keefe CJ, Wilson PWF, Schaefer EJ. Reference intervals for plasma apolipoprotein A-I as determined with a commercially available immunoturbidometric assay: Results from the Framingham Offspring Study. Clin Chem 1996;42:507-14.
27. Contois JH, McNamara JR, Lammi-Keefe CJ, Wilson PWF, Schaefer EJ. Reference intervals for plasma apolipoprotein B as determined with a commercially available immunoturbidometric assay: Results from the Framingham Offspring Study. Clin Chem 1996;42:515-23.
28. McNamara JR, Nakajima K, Fukuda Y, Ordovas JM, Schaefer EJ. Direct measurement of lipoprotein remnants with an antibody-based test [Abstract]. Clin Chem 1996;42:S288-9.
29. Expert Panel. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. (Adult Treatment Panel II). Circulation 1994;89:1329-1433.
30. Genest JJ Jr, McNamara JR, Ordovas JM, Jenner JL, Silberman SR, Anderson KM, et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992;19:792-802.
31. Sandkamp M, Funke H, Schulte H, Koher E, Assmann G. Lipoprotein (a) is an independent risk factor for myocardial infarction at a young age. Clin Chem 1990;36:20-3.
32. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE, et al. Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1994;271:999-1003.
33. Hokanson JE, Austin MA. Plasma triglyceride level as a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-9.
34. Uiterwaal CSPM, Grobbee DE, Witteman JCM, van Stiphout W-AHJ, Krauss XH, Havekes LM, et al. Postprandial triglyceride response in young adult men and familial risk for coronary atherosclerosis. Ann Intern Med 1994;121:576-83.
35. Meyer E, Westerveld HT, de Ruyter-Meijstek FC, van Greevenbroek MMJ, Rienks R, van Rijn HJM, et al. Abnormal postprandial apolipoprotein B-48 and triglyceride responses in normolipidemic women with greater than 70% stenotic coronary artery disease: a case-control study. Atherosclerosis 1996;124:221-35.
36. McNamara JR, Shah PK, Nelson SM, Nakajima K, Wilson PWF, Schaefer EJ. Lipoprotein remnant cholesterol and triglyceride values in coronary cases and Framingham controls [Abstract]. Circulation 1996;94:1-94.
37. Zilversmit DB. Atherogenic nature of triglycerides, postprandial lipemia, and triglyceride-rich remnant lipoproteins. Clin Chem 1995;41:153-8.
38. McNamara JR, Campos H, Ordovas JM, Peterson J, Wilson PWF, Schaefer EJ. Effect of gender, age, and lipid status on low density lipoprotein subfraction distribution: results of the Framingham Offspring Study. Arteriosclerosis 1987;7:483-90.
39. Campos H, Genest JJ Jr, Blijlevens E, McNamara JR, Jenner JL, Ordovas JM, et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 1992;12:187-95.
40. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996;276:875-81.
41. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979;60:473-85.
42. Tatami R, Mabuchi H, Ueda K, Ueda R, Haba T, Kametani T, et al. Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease. Circulation 1981;64:1174-84.
43. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993;88:2762-70.
44. Mjøs OD, Faergeman O, Hamilton RL, Havel RJ. Characterization of remnants produced during the metabolism of triglyceride-rich lipoproteins of blood plasma and intestinal lymph in the rat. J Clin Invest 1975;56:603-15.
45. Pagnan A, Havel RJ, Kane JP, Kotite L. Characterization of human very low density lipoproteins containing two electrophoretic populations: double prebeta lipoproteinemia and primary disbetalipoproteinemia. J Lipid Res 1977;18:613-22.
46. Takeichi S, Nakajima Y, Osawa M, Yukawa N, Saito T, Seto Y, et al. The possible role of remnant-like particles as a risk factor for sudden cardiac death. Int J Legal Med 1997;110:213-9.
47. Shimizu H, Mori M, Saito T. An increase of serum remnant-like particles in non-insulin-dependent diabetic patients with microalbuminuria. Clin Chim Acta 1993;221:191-6.
48. Nakajima N, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, et al. A new approach for the detection of Type III hyperlipoproteinemia by RLP-cholesterol assay. J Atheroscler Thromb 1994;1:30-6.
49. Seman LJ, Jenner JL, McNamara JR, Schaefer EJ. Quantitation of plasma lipoprotein (a) by cholesterol assay of lectin-bound lipoprotein (a). Clin Chem 1994;40:400-3.